Pulmonary NO synthase inhibition and inspired CO₂: effects on V'/Q' and pulmonary blood flow distribution


ABSTRACT: Inhaled carbon dioxide decreases ventilation/perfusion ratio (V'/Q') heterogeneity in dogs. The aim of this study was to test whether inhaled CO₂ improves the V'/Q' by inhibition of nitric oxide production and whether inhibition of endogenous NO production in the lung alters gas exchange and V'/Q' matching.

Eleven healthy dogs were anaesthetized and mechanically ventilated. The multiple inert gas elimination technique (MIGET) was used to measure V'/Q' heterogeneity and regional pulmonary blood flow heterogeneity was assessed in five dogs using fluorescent microspheres. In a separate set of five dogs, exhaled NO levels were measured via chemiluminescence. All dogs were studied before and after 4.8% inspired CO₂, and then given the NO synthase inhibitor Nω-nitro-1-arginine methyl ester (L-NAME, 10 mg·kg⁻¹) via nebulization, after which they were studied again with room air and inhaled CO₂.

CO₂ and L-NAME improved arterial and alveolar oxygen tension, but the improvements with L-NAME did not reach statistical significance. Improved V'/Q' matching, as assessed by the MIGET, occurred under all experimental conditions. Exhaled NO levels were reduced by 40% with CO₂ and 70% with L-NAME. The standard deviation of regional pulmonary blood flow assessed via microspheres decreased only with inhaled CO₂. Fractal analysis of pulmonary blood flow distributions revealed that regional blood flow was highly correlated with flow to neighbouring pieces of lung in all four conditions with no changes in the fractal dimension.

Inspired carbon dioxide improves ventilation perfusion ratio matching and is associated with a more homogeneous distribution of pulmonary blood flow. Although inspired carbon dioxide causes a reduction in exhaled nitric oxide, the differences in pulmonary perfusion distributions found between carbon dioxide and Nω-nitro-1-arginine methyl ester suggest that the carbon dioxide effect is not mediated by a reduction in nitric oxide production. The improved ventilation perfusion ratio matching with inhibition of nitric oxide synthase suggests the intriguing possibility requiring further study that endogenous production of nitric oxide in the lung does not subserve ventilation perfusion ratio regulation.


Addition of low concentrations (2–5%) of carbon dioxide to inspired gas improves gas exchange and arterial oxygenation in normal lungs [1, 2]. Using the multiple inert gas elimination technique (MIGET), it was demonstrated that inspired CO₂ reduces ventilation/perfusion ratio (V'/Q') heterogeneity even with constant ventilation [3]. Although CO₂ has many effects on the lungs that may promote V'/Q' matching [4, 5], it remains unknown how and at what site(s) CO₂ decreases V'/Q' heterogeneity.

Changes in CO₂ concentration or the accompanying pH may affect airways, parenchyma or vessels directly or indirectly through modulation of effector substances such as prostaglandins [6] or calcium [7]. Of considerable interest, also, is nitric oxide, which is vaso- and bronchodilating [8, 9] as well as a neurotransmitter in nonadrenergic non-cholinergic nerves [10]. Thus changes in local NO production may alter vascular and bronchial tone to regulate the local V'/Q'. NO synthase (NOS), which catalyses the conversion of L-arginine to NO and L-citrulline, is sensitive to changes in pH, and in general is inhibited by acidosis [11–16]. In the guinea-pig, 6% CO₂ causes a reduction in exhaled NO of 60% [17] and, in the rabbit, of 30% [18]. In the isolated perfused rabbit lung, low concentrations of CO₂ cause a decrease in levels of exhaled NO [19] and NO metabolites measured in the perfusate [20].

These experiments show that alterations in CO₂ concentration affect NO production in the lung, suggesting that inspired CO₂ might elicit its effects on V'/Q' heterogeneity through changes in NO metabolism in the airways, nerves or vessels. It was hypothesized that inhibition of lung NOS should mimic the effect of inhaled CO₂ on V'/Q' relationships in the lung and not further reduce V'/Q' heterogeneity when combined with CO₂. In order to
test whether the mechanism of action of inspired CO₂ on \( V'/Q' \) matching results from altering NO production and to examine whether endogenous NO formation, itself, affects \( V'/Q' \) heterogeneity and pulmonary blood flow distribution, nebulized \( N^\circ \)-nitro-L-arginine methyl ester (L-NAME), a nonspecific inhibitor of NOS, was administered. This method of L-NAME administration was chosen to limit NOS blockade to the lung and minimize systemic NOS inhibition. \( V'/Q' \) relationships were examined via the MIGET and regional pulmonary blood flow was assessed using fluorescent microspheres. Effects on lung NO production were measured via changes in exhaled NO levels analysed by chemiluminescence.

## Methods

### Animal instrumentation and support

Studies were performed on healthy mixed-breed dogs (weight range, 20–28 kg) in the supine position under barbiturate anaesthesia (20–30 mg·kg\(^{-1}\) i.v. sodium pentothal induction with supplemental doses, 1–2 mg·kg\(^{-1}\) as needed every 30–60 min). The animals were intubated with a cuffed endotracheal tube. Femoral arterial and venous catheters and a jugular 7-F thermodilution catheter were inserted. Temperatures were monitored with a rectal thermometer. Ventilation was administered by means of a piston pump ventilator at a tidal volume of 12–13 mL·kg\(^{-1}\)·min\(^{-1}\) and a frequency of 14–16 breaths·min\(^{-1}\). The ventilator was supplied with gas from tanks that were free of NO (as measured in the inspiratory gas by mass spectrometer). Every 5 min, a single 30-mL·kg\(^{-1}\)·breath was provided to prevent atelectasis. Once an acceptable rate of ventilation was determined via arterial blood gas analysis (arterial pH, 7.39–7.45; arterial carbon dioxide tension \( (P_a,CO_2) \), 4.3–4.7 kPa (32–35 mmHg)), no further changes were made to the ventilator settings. Following the experiment, the dogs were sacrificed by means of an overdose of sodium thiopental. All aspects of procurement, care, nutrition, anaesthetic use and euthanasia in these experiments followed the guidelines of the American Physiological Society (published regularly in the *Journal of Applied Psychology*) for the protection of vertebrate animals used for experimental and other scientific purposes.

### Haemodynamics and respiratory gas exchange measurements

Pulmonary and systemic arterial pressures, airway pressures, and mixed expired carbon dioxide (\( P_{CO_2} \)) and oxygen tension \( (P_a,O_2) \) were continuously recorded on an eight-channel recorder (Hewlett-Packard, Palo Alto, CA, USA). At specified intervals, pulmonary artery occlusion pressure, thermodilution cardiac outputs and mixed expired \( P_a,O_2 \) and \( P_a,CO_2 \) (sampled from a 3-L mixing box) were determined. The \( P_a,O_2 \) and \( P_a,CO_2 \) in expired gas were measured using a mass spectrometer (Perkin-Elmer Medical Gas Analyzer MGA-1100; Perkin-Elmer Norwalk, CT, USA). Blood pH and oxygen and carbon dioxide tension were measured in arterial \( (P_a,O_2 \) and \( P_a,CO_2 \)) and mixed venous \( (P_v,O_2 \) and \( P_v,CO_2 \)) blood using a blood gas analyser (Radiometer BMS-3; Radiometer America, Westlake, OH, USA) maintained at 37 °C and corrected to the measured temperature. Oxygen consumption \( (V',O_2) \) and carbon dioxide production \( (V',CO_2) \) were calculated by analysis of expired gases using appropriate temperature, pressure and water content corrections.

Respiratory gas exchange was assessed by analysis of arterial and mixed venous blood gas levels. In calculating the alveolar/arterial tension difference for oxygen, \( (P_a,O_2 - P_a,CO_2) \), the complete alveolar gas equation incorporating inspiratory carbon dioxide fraction \( (F,CO_2) \) [3] was used:

\[
P_a,O_2 = \frac{R \cdot (P_I,O_2 + P_v,CO_2 - P_a,CO_2) \cdot [1 - (1 - R) \cdot F,CO_2]}{R + (1 - R) \cdot F,CO_2}
\]

(1)

where \( R \) is the respiratory gas exchange ratio \( (V',CO_2/V',O_2) \), \( P_I,O_2 \) and \( P_v,CO_2 \) are the inspiratory oxygen and carbon dioxide tension, \( P_I,CO_2 \) is the inspiratory oxygen fraction, and \( P_a,O_2 \) is the alveolar oxygen tension. \( P_a,CO_2 \) was assumed to be the same as alveolar carbon dioxide tension.

### Inert gas exchange measurements

\( V'/Q' \) relationships were determined by means of the MIGET [21, 22] using constant infusion of a dilute solution of six inert gases (sulphur hexafluoride, ethane, cyclopropane, halothane, diethyl ether and acetone) dissolved in 5% dextrose as described by Wagner and coworkers [21, 22]. The gas extraction method of Wagner et al. [21] was used to determine inert gas tensions and solubilities in blood samples. Inert gas indices were calculated from the 50-compartment model of Wagner et al. [21]. \( V'/Q' \) heterogeneity was also assessed by the arterial/alveolar inert gas difference area \((a-A)D \) area; an integrated value of the subtraction of areas bounded by the alveolar and arterial tensions of the six inert gases when plotted against blood gas solubility on a log scale) derived directly from the retention and excretion data [23]. All inert gas data are the mean of duplicate measurements.

### Experimental protocols

Each dog underwent the same protocol, serving as its own control. After stabilization and a 20-min period of ventilation with room air, baseline haemodynamic (cardiac output, cardiac frequency, and systemic and pulmonary artery pressures), ventilation and respiratory gas exchange (arterial and mixed venous blood gas levels, minute ventilation, airway pressures, and \( V',O_2 \) and \( V',CO_2 \)), and inert gas exchange measurements were taken. Following these measurements, the animal was ventilated with 48.8% CO₂ (as measured in the inspiratory gas by mass spectrometer) and 20.9% O₂. After 20 min, all measurements were repeated and the animal was then returned to room air ventilation. Next, 40 mg·mL\(^{-1}\) L-NAME in saline was nebulized using an updraft nebulizer until systemic blood pressure rose by ≥10%. This required a mean total nebulized dose of 10–15 mg·kg\(^{-1}\).

L-NAME was administered by nebulization with the aim of generating a slight increase in systemic blood pressure to ensure maximal lung NOS inhibition but to avoid the profound systemic hypertension, cardiac output depression and \( P_v,O_2 \) reduction that occur when large doses of L-NAME are given systemically [24]. Hence, it was attempted to minimize the potential extrapulmonary influences of L-NAME on \( V'/Q' \) heterogeneity [25]. Twenty minutes later, all measurements were repeated. Then, while the
slight systemic hypertensive effect of nebulized l-NAME was still measurable (indicating a sustained level of NOS inhibition), the dog was ventilated with 4.8% CO₂ for 20 min and all measurements repeated. The steps of ventilation with room air and CO₂ were alternated in successive dogs.

**Microsphere injection**

In the final five dogs, changes in pulmonary blood flow were measured using injectable fluorescent microspheres. Fluorescent 15-μm-diameter microspheres (Fluospheres; Molecular Probes, Eugene, OR, USA) of six different colours (red, crimson, scarlet, orange, yellow-green and blue-green) were injected through an i.v. catheter in a superficial leg vein over 30 s in 5 mL normal saline, followed by a 10-mL saline flush. The microspheres were sonicated and agitated on a vortex mixer before injection. During each of the four experimental conditions, at the time that other measurements were taken, one colour of microsphere was injected.

Following completion of the experiment, the animals were deeply anaesthetized, given heparin, exsanguinated and killed by intravenous pentobarbital sodium injection. A sternotomy was performed, large-bore catheters were placed in the pulmonary artery and left atrium and the thoracic aorta was tied off. The lungs were perfused with normal saline and 2% dextran (74,000 Da) until clear of blood, removed from the chest and allowed to dry inflated at an airway pressure of 25 cmH₂O.

When dry, the lungs were coated with Kwik foam (DAP Inc., Dayton, OH, USA), suspended vertically in a plastic-lined square box and embedded in rapidly setting urethane foam (908gm polyol and isocyanate; International Sales, Seattle, WA, USA) to create a rigid form to which a three-dimensional co-ordinate system could be applied. The foam block was then cut into uniform slices and the sections cored using a 1-cm coring tool. Foam adhering to the lung pieces was removed. Each lung piece was weighed and assigned a three-dimensional co-ordinate and lobe designation.

The fluorescent signals for each colour were determined by extracting the fluorescent dyes from each piece with an organic solvent and then measuring the concentrations of fluorescence in each sample [26]. The dataset for each dog consisted of x, y, and z co-ordinates, lobe designation, weight and relative flow for each lung piece. The relative blood flow to each lung piece was divided by the weight of each piece and normalized to the mean, providing a relative weight-normalized flow per piece.

**Measurement of exhaled nitric oxide**

In order to evaluate the extent of pulmonary NOS inhibition by inhaled l-NAME and CO₂, exhaled NO levels were measured via chemiluminescence (nitric oxide analyzer 2700B; Sievers, Boulder, CO, USA) in a separate set of five dogs ventilated with NO-free gas. The mixed expired gas was continuously sampled for NO from the expiratory mixing box. The analyser was connected to a Strawberry Tree Workbench V3.04 (Strawberry Tree, Inc., Sunnyvale, CA, USA) for continuous recording and calibrated to NO-free gas.

**Statistical analysis**

All data are presented as mean±SD and were analysed by analysis of variance followed by Scheffé’s and Bonferroni/Dunn post hoc tests corrected for multiple comparisons of similar data sets and for comparisons over time. Differences between individual experimental points were analysed by means of the Wilcoxon signed-rank test. The Pearson correlation coefficient calculated between perfusion to lung pieces within a dog was used to quantify the relationship between regional perfusion under different conditions. The coefficient of variation (CV) was used to characterize perfusion heterogeneity within each dog over space or time.

Additionally, fractal analysis of the microsphere data for all five dogs was performed for all conditions, following the method of GLENNY and ROBERTSON [27]. Briefly, fractal analysis represents an approach to the characterization of organ blood flow heterogeneity independent of scale of tissue sampled. The fractal dimension is calculated from the coefficient of blood flow to individual pieces of lung. Small neighbouring lung pieces are combined into a larger conglomerate piece based on multiples (2, 3, 4, 6, 8, 12, 16, 24, 32, 48 and 64) of the initial central piece-size. The CV of blood flow is then calculated as if the lung had been divided into the larger conglomerate pieces. Conglomerates are restricted to lie entirely within the right or left lung but may traverse lobes. The algorithm for dividing the lung in this way is repeated for each conglomerate of n pieces a total of n times, obtaining n CVs. The mean of the logarithm of the n CVs is used for regression modelling to obtain the fractal dimension (D). The so of the logarithm of the n CVs is used for plotting error bars. The total number of conglomerate pieces for all n repetitions is used as the regression weight at piece n. LogCV is plotted against logpiece-size and a regression line obtained using weighted regression analysis. The D is calculated from 1 - slope, where slope is obtained from the regression line fitted to the logCV versus logpiece-size data.

A p-value of <0.05 was considered statistically significant.

**Results**

The haemodynamic, ventilatory and metabolic effects of 4.8% CO₂, l-NAME and CO₂ following l-NAME are listed in table 1. Mean systemic blood pressure increased significantly with l-NAME and with l-NAME plus CO₂. Pulmonary artery pressure increased under all three experimental conditions, approaching statistical significance with l-NAME alone (p=0.061) and achieving significance with l-NAME plus CO₂. Pulmonary vascular resistance (PVR) increased significantly after both l-NAME and CO₂ following l-NAME are listed in table 1. Mean systemic blood pressure increased significantly with l-NAME and with l-NAME plus CO₂.

Pulmonary capillary occlusion pressure, peak airway pressure, haematocrit and temperature did not change significantly under any of the experimental conditions. Minute ventilation was fixed throughout at 6.4±1.01 L min⁻¹ as was the FiO₂ at 0.209.
Inhalation of CO₂ significantly increased arterial oxygen tension (A-O₂) and arterial carbon dioxide tension (A-CO₂) with inspired CO₂ following nebulized L-NAME. Inert gas excretion component of the (a-A)D area was reduced significantly under all experimental conditions. The retention of CO₂ was reduced with inhaled CO₂, suggesting decreased heterogeneity of regional pulmonary blood flow (table 4). Further analysis of the microsphere data revealed a pattern consistent with fractal structure, as given by a fractal dimension of ~1.14. Regional blood flow in the lung is distributed in three-dimensional space, but, when characterized as a relative dispersion, the heterogeneity of the flow is decreased to a space with fractal dimension of 1.0–1.5 [27]. The greater the irregularity of the flow, the greater the fractal dimension. Neither inhaled CO₂ nor l-NAME altered this dimension. Regression analysis of changes in regional pulmonary blood flow showed no significant alterations over time.

**Discussion**

The major findings of this study are that inspired CO₂ and inhibition of pulmonary NOS (inhaled l-NAME) improve V/Q heterogeneity but act in different fashions. Like l-NAME, inhaled CO₂ caused a reduction in exhaled NO levels, but decreased V/Q heterogeneity, at least in part, by decreasing the heterogeneity of regional pulmonary blood flow distribution. In contrast, l-NAME improved V/Q heterogeneity but did not alter regional pulmonary blood flow. l-NAME did not add to the improvement in V/Q matching already produced by inhaled CO₂. Inhaled CO₂ reduces exhaled NO levels but its effect on pulmonary blood flow suggests that improved V/Q matching with inspired CO₂ is not mediated by a reduction in NO production. Lastly, these results suggest that endogenous NO production in the normal dog lung does not subserve V/Q regulation.

**Table 1. – Respiratory gas exchange measurements**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Baseline</th>
<th>CO₂</th>
<th>l-NAME</th>
<th>CO₂ + l-NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO₂ mmHg</td>
<td>113±16</td>
<td>114±20</td>
<td>12±17*</td>
<td>12±17*</td>
</tr>
<tr>
<td>PaCO₂ mmHg</td>
<td>14.6±4.1</td>
<td>16.2±5.7</td>
<td>16.0±5.9</td>
<td>19.2±7.4*</td>
</tr>
<tr>
<td>Q̇ CO₂ L.min⁻¹</td>
<td>3.9±0.9</td>
<td>4.5±1.0*</td>
<td>3.8±0.6</td>
<td>3.8±0.8</td>
</tr>
<tr>
<td>PAOP mmHg</td>
<td>6.4±2.2</td>
<td>6.7±1.9</td>
<td>6.0±2.4</td>
<td>6.6±2.7</td>
</tr>
<tr>
<td>V̇ O₂ L.min⁻¹</td>
<td>0.15±0.045</td>
<td>0.142±0.0247</td>
<td>0.155±0.058</td>
<td>0.144±0.056</td>
</tr>
<tr>
<td>V̇ CO₂ L.min⁻¹</td>
<td>0.139±0.053</td>
<td>0.128±0.050</td>
<td>0.15±0.06*</td>
<td>0.147±0.054</td>
</tr>
<tr>
<td>PVR dyne-cm⁻⁵</td>
<td>212±60</td>
<td>218±56</td>
<td>265±98*</td>
<td>349±102*</td>
</tr>
</tbody>
</table>

Data are presented as mean±sd. l-NAME: N⁶-nitro-arginine methyl ester; SBP: mean systemic blood pressure; PPa: mean pulmonary artery pressure; Q̇ : cardiac output; PAOP: pulmonary artery occlusion pressure; V̇ O₂: oxygen consumption; V̇ CO₂: carbon dioxide production; PVR: pulmonary vascular resistance. *: p<0.05 versus baseline. (1 mmHg=0.133 kPa.)
inhaled L-NAME (Table 1), consistent with other studies were followed. Pulmonary pressures and PVR rose with study, pulmonary and systemic haemodynamic parameters pulmonary NOS inhibition was achieved in the present response studies with aerosolized NOS inhibitors.

Sorbed systemically. To date, there have been no dose/ activity of NOS inhibitors when delivered as aerosols certain questions remain unanswered. No study of inhaled NOS inhibitors describes what portion of the dose reaches the pulmonary NO production is altered and how much is ab-
alveoli and the pulmonary vasculature, to what extent pul-
monary NO production is altered and how much is ab-
sorbed systemically. To date, there have been no dose/ response studies with aerosolized NOS inhibitors.

In order to show that a selective and high degree of pulmonary NOS inhibition was achieved in the present study, pulmonary and systemic haemodynamic parameters were followed. Pulmonary pressures and PVR rose with inhaled L-NAME (Table 1), consistent with other studies using high-dose intravenous NOS inhibitors but much less systemic vasoconstriction was observed [8, 24, 32]. This suggests a high but more selective blockade of lung NO production.

Since exhaled NO measurements were not available in these dogs, a further experiment was performed in five separate dogs in which exhaled NO levels were measured following inspired CO2, L-NAME and a combination of the two. Dogs have very low baseline levels of exhaled NO compared to several other species [19]. Nevertheless, a statistically significant decline in exhaled NO levels was demonstrated in these five dogs under all experimental conditions. Furthermore, haemodynamic changes (data not shown) in this separate set of experiments were similar in magnitude to those found in the original dogs. These data suggest that significant blockade of pulmonary NOS was produced in the initial set of experiments and similar reductions in exhaled NO levels were probably achieved.

Although greater and possibly complete NOS inhibition could have been achieved in the lung with higher doses, L-
NAME nebulization was discontinued when the mean systemic arterial pressure rose by ~10% above baseline. The aim of delivering L-NAME via aerosol was to limit its impact on systemic vascular resistance and cardiac output since reduced cardiac output (<25% reduction) can itself lead to increased V’/Q’ heterogeneity [33]. In this way, essentially no change in cardiac output was observed (Table 1).

The order of baseline conditions and NOS inhibition could not randomly be reversed due to the long duration of action of L-NAME, which inhibits NOS by >90% [34] and causes sustained systemic hypertension for up to 2–4 h when given intravenously in dogs and rabbits [34, 35]. The sustained elevation of pulmonary artery and systemic blood pressure into the last measurement period suggests that there was a constant and near-maximal state of NOS inhibition following L-NAME nebulization throughout the last two experimental periods.

Although clinically healthy animals were studied, it is clear that baseline V’/Q’ distributions were abnormal in these dogs. Included in this group were several older dogs and this, in combination with mechanical ventilation, anaesthesia and the supine position, may have exaggerated their V’/Q’ abnormality. Despite the unexpected greater V’/Q’ heterogeneity (increased logQ’ SD and logV’ SD with normal shunt values), all the dogs tolerated the entire protocol without evident respiratory, haemodynamic or metabolic deterioration.

Differences between effects of Nω-nitro-l-arginine methyl ester and carbon dioxide on gas exchange and haemodynamics

Despite similar improvements in V’/Q’ heterogeneity, as measured by the MIGET, L-NAME produced a smaller increase in arterial oxygenation than inspired CO2. Several factors may help to explain this difference. First, inspired CO2 caused a reduction in V’/Q’, which led to a statistically significantly higher PaCO2. In contrast, there was no change in V’/Q’ with L-NAME, confirming similar previous observations in dogs [36]. Secondly, respiratory acidosis

**Critique of methods**

Both inhaled NO and nebulized L-NAME [28] have been used to examine V’/Q’ relationships [28, 29] but this report represents the first use of inhaled NOS inhibitors in the evaluation of V’/Q’ heterogeneity in healthy animals. Despite widespread intravenous employment, the use of NOS inhibitors as inhaled agents has been limited. Aerosolized NOS inhibitors magnify the response to bronchoconstrictor and pulmonary vasoconstrictor challenges [9, 30] and reduce exhaled NO levels in asthmatic patients [31]. Although these studies demonstrate the activity of NOS inhibitors when delivered as aerosols certain questions remain unanswered. No study of inhaled NOS inhibitors describes what portion of the dose reaches the alveoli and the pulmonary vasculature, to what extent pulmonary NO production is altered and how much is absorbed systemically. To date, there have been no dose/response studies with aerosolized NOS inhibitors.

In order to show that a selective and high degree of pulmonary NOS inhibition was achieved in the present study, pulmonary and systemic haemodynamic parameters were followed. Pulmonary pressures and PVR rose with inhaled L-NAME (Table 1), consistent with other studies using high-dose intravenous NOS inhibitors but much less systemic vasoconstriction was observed [8, 24, 32]. This suggests a high but more selective blockade of lung NO production.

Since exhaled NO measurements were not available in these dogs, a further experiment was performed in five separate dogs in which exhaled NO levels were measured following inspired CO2, L-NAME and a combination of the two. Dogs have very low baseline levels of exhaled NO compared to several other species [19]. Nevertheless, a statistically significant decline in exhaled NO levels was demonstrated in these five dogs under all experimental conditions. Furthermore, haemodynamic changes (data not shown) in this separate set of experiments were similar in magnitude to those found in the original dogs. These data suggest that significant blockade of pulmonary NOS was produced in the initial set of experiments and similar reductions in exhaled NO levels were probably achieved.

Although greater and possibly complete NOS inhibition could have been achieved in the lung with higher doses, L-
NAME nebulization was discontinued when the mean systemic arterial pressure rose by ~10% above baseline. The aim of delivering L-NAME via aerosol was to limit its impact on systemic vascular resistance and cardiac output since reduced cardiac output (<25% reduction) can itself lead to increased V’/Q’ heterogeneity [33]. In this way, essentially no change in cardiac output was observed (Table 1).

The order of baseline conditions and NOS inhibition could not randomly be reversed due to the long duration of action of L-NAME, which inhibits NOS by >90% [34] and causes sustained systemic hypertension for up to 2–4 h when given intravenously in dogs and rabbits [34, 35]. The sustained elevation of pulmonary artery and systemic blood pressure into the last measurement period suggests that there was a constant and near-maximal state of NOS inhibition following L-NAME nebulization throughout the last two experimental periods.

Although clinically healthy animals were studied, it is clear that baseline V’/Q’ distributions were abnormal in these dogs. Included in this group were several older dogs and this, in combination with mechanical ventilation, anaesthesia and the supine position, may have exaggerated their V’/Q’ abnormality. Despite the unexpected greater V’/Q’ heterogeneity (increased logQ’ SD and logV’ SD with normal shunt values), all the dogs tolerated the entire protocol without evident respiratory, haemodynamic or metabolic deterioration.

**Differences between effects of Nω-nitro-l-arginine methyl ester and carbon dioxide on gas exchange and haemodynamics**

Despite similar improvements in V’/Q’ heterogeneity, as measured by the MIGET, L-NAME produced a smaller increase in arterial oxygenation than inspired CO2. Several factors may help to explain this difference. First, inspired CO2 caused a reduction in V’/Q’, which led to a statistically significantly higher PaCO2. In contrast, there was no change in V’/Q’ with L-NAME, confirming similar previous observations in dogs [36]. Secondly, respiratory acidosis
with inspired CO₂ causes a rightward shift of the haemoglobin/oxygen dissociation curve (Bohr effect). Since both a higher PAO₂ and a rightward shift of the haemoglobin/oxygen dissociation curve reduce PAO₂ for any given PAO₂ and venous admixture [37], inspired CO₂ would be expected to generate a higher PAO₂ than L-NAME despite equal V′/Q′ heterogeneity reduction. Both CO₂ and L-NAME elicited modest increases in pulmonary artery pressure but PVR was increased only with L-NAME.

Effects of inspired carbon dioxide and nitric oxide synthesis inhibition on ventilation/perfusion ratio heterogeneity

Both inspired CO₂ and inhaled L-NAME improved V′/Q′ matching. The improvement in V′/Q′ with inhaled L-NAME is a novel finding and accords with the results of Venegas et al. [38], who found that inhaled NO (40 parts per million (ppm)) increased the spatial heterogeneity of V′/Q′ in supine dogs measured by positron emission tomography, although Hopkins et al. [39] found no V′/Q′ deterioration in anaesthetized dogs given 80 ppm NO. Deterioration in V′/Q′ matching with inhaled NO has also been shown in studies of patients with chronic obstructive pulmonary disease [40] and in normal humans [40, 41]. Two recent studies found a trend towards better gas exchange with partial elimination or diversion of endogenous NO production. Settergren et al. [42] eliminated the autoinhalation of nasal and sinus NO in humans and Fagan et al. [43] abolished endothelial cell production of NO in a knockout mouse deficient in endothelial NOS. These findings strongly suggest the intriguing possibility that endogenous basal NO production in the lung or upper respiratory tract does not serve the purpose of regulating V′/Q′. The basis for worsened gas exchange and increased V′/Q′ heterogeneity with inhaled NO and their improvement with NOS inhibition in lungs without significant shunt may, in part, represent release of hypoxic pulmonary vasoconstriction (HPV) by NO [8] and enhanced HPV with NOS inhibition [29, 44]. Supporting the concept that increased HPV may improve gas exchange, it has been shown that ventilation with slightly hypoxic air (FlO₂, 0.15) in dogs reduces V′/Q′ heterogeneity [3]. However, this may not be the entire explanation as predominantly greater improvement with NOS inhibition of the retention component of the (a-A)D area, which should reflect a reduction in the number of lung units with low V′/Q′ as HPV is enhanced, was not found.

The ability of inspired CO₂ to reduce V′/Q′ heterogeneity probably stems from some combination of its multiple effects on airways, nerves, parenchyma and vessels [4, 5]. CO₂ dilates small airways and improves collateral ventilation but can evoke vagally mediated large airway bronchoconstriction [45–48]. Ingram [2] found that parenchymal compliance was increased with inspired CO₂, possibly as a result of enhanced surfactant function at a more acid pH [49]. The vascular effects of CO₂ are not as easily described since low pH causes vasoconstriction and enhances HPV [50], but, in some experimental situations, there may be a direct opposing vasodilator effect of molecular CO₂ [51, 52].

Although it was the authors’ original hypothesis that inspired CO₂ might reduce V′/Q′ heterogeneity by suppressing lung NO production, the data did not support this concept. First, CO₂ reduced regional perfusion heterogeneity but this did not occur when even greater suppression of NO production was achieved with L-NAME. Secondly, although exhaled NO levels fell with inspired CO₂, this may be partially due to the increased cardiac output and thus greater NO scavenging by haemoglobin [35]. Finally, CO₂ has significantly greater effects on airway tone than vascular tone [5], whereas the opposite is true for NO [53, 54].

Both CO₂ and L-NAME may improve V′/Q′ matching through changes in regional ventilation distribution which were not directly measured. There were no changes in airway pressures during fixed ventilation with L-NAME or CO₂, but more sophisticated measurement of airway resistance and direct measurement of regional ventilation (such as with simultaneous inhaled and injected microspheres) would be necessary to assign changes in bronchomotor tone and ventilation as contributors to the CO₂ or the L-NAME effect.

The finding of improved V′/Q′ matching and decreased V′O₂ and V′CO₂ in these dogs may represent further justification for the clinical application of permissive hypoxaemia [55]. In fact, these results may suggest a rationale for the careful addition of exogenous CO₂ to inspired gas. However, it must be stated that these experiments were not performed under conditions of lung injury or multiple system organ dysfunction. Furthermore, although inhaled L-NAME also improved V′/Q′ matching, the ubiquity and many functions of the NO system require further study before using inhaled L-NAME to help in the face of severe hypoxaemic respiratory failure.

In conclusion, it was found that inhibition of lung nitric oxide synthase and loss of endogenous nitric oxide production reduces ventilation/perfusion ratio heterogeneity. This intriguing finding suggests that endogenous nitric oxide production plays no important role in ventilation/perfusion ratio regulation; however, further study is necessary. Although inspired carbon dioxide caused a reduction in exhaled nitric oxide levels, it is unlikely that this entirely explains how inspired carbon dioxide improves gas exchange. Inspired carbon dioxide narrowed the heterogeneity of pulmonary blood flow, which was not seen with nitric oxide synthase inhibition. Whether inspired carbon dioxide and nitric oxide synthase inhibitors act similarly in other ways to reduce ventilation/perfusion ratio heterogeneity or by separate mechanisms will require more investigation from the cellular level to the whole animal.

Acknowledgements. The authors wish to thank M. Middaugh, T. Tran and M. Kerr for their excellent technical contributions in these studies.

References


35. Persson MG, Longivist PA, Gustafsson LE. Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits. *Anesthesiology* 1995; 82: 969–974.


38. Venegas J, Trepo S, Mialovici S, Zapol W, Hales G. Effects of inhaled NO in the spatial heterogeneity of
pulmonary perfusion ($Q'$), ventilation ($V'$), and $V'/Q'$.


